Due to COVID-19, the drug has consistently achieved robust sales since its introduction
With activist investors bemoaning returns on R&D and M&A investment and the loss of about $17bn in revenues looming from exclusivity expiries in 20252030, the company has been culling its pipeline and looking externally for assets
Additionally, 49% of patients on the 30 mg dose achieved HbA1c levels below 7%, compared to only 21% in the placebo group
Market Segmentation Global Glucagon-Like Peptide-1 Agonists Market Size, Share & Industry Analysis, By Product Type (Short-Acting GLP-1 Agonists, Long-Acting GLP-1 Agonists), By Route of Administration (Injectable, Oral), By Application (Type 2 Diabetes, Obesity Management, Cardiovascular Disease Management), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Analysis and Forecast 20262035 Global Glucagon-Like Peptide-1 Agonists Market Size & Statistics The Market size of global glucagon-like peptide-1 agonists was estimated to be worth USD 46.18 Billion in 2025
In 2021, the annual sales of the drug surpassed $10 billion for the first time, reaching $10.76 billion
AstraZeneca Roche Novartis Pfizer Amgen Bristol Myers Squibb GSK Sanofi Takeda Regeneron These companies are shaping the future of healthcare through groundbreaking therapies, strategic acquisitions, and robust R&D pipelines
